Breaking News Instant updates and real-time market news.

AMRN

Amarin

$3.19

0.03 (0.95%)

06:04
09/13/17
09/13
06:04
09/13/17
06:04

Amarin appoints Mark W. Salyer to new position of Chief Commercial Officer

Amarin announced that Mark W. Salyer has joined Amarin as Chief Commercial Officer, a newly created position. Most recently, Salyer was at Teva Pharmaceuticals as Executive Vice President and General Manager of Teva Respiratory.

  • 25

    Sep

AMRN Amarin
$3.19

0.03 (0.95%)

06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/17
06/29/17
NO CHANGE
Target $7

Buy
Jefferies boosts Amarin target to $7 ahead of mid-2018 data
Jefferies analyst Matthew Andrews views Amarin's risk/reward as favorable into the Vascepa mixed dyslipidemia data in mid-2018. Positive data could support a "paradigm shift" in treating the 70M mixed dyslipidemia patients with high trigylcerides and lead to broader Vascepa use, Andrews tells investors in a research note. The analyst assigns a 55% probability of positive REDUCE-IT trial data and models $1.3B in peak-adjusted sales. He sees a floor of $2 per share with negative data and long-term upside to $17 per share over the long-term with positive data. The analyst boosted his price target for Amarin shares to $7 from $5 and keeps a Buy rating on the name. The stock closed yesterday at $3.78.
08/03/17
HCWC
08/03/17
NO CHANGE
Target $10
HCWC
Buy
Amarin valuation attractive into interim data, says H.C. Wainwright
Amarin's current valuation is supported by the "strong" underlying Vascepa sales alone, H.C. Wainwright analyst Andrew Fein tells investors in a post-earnings research note. He believes the recent share pullback provides an opportunity for a "free shot" at the upcoming interim look of the REDUCE-IT trial. Investors are ascribing no value to the interim nor full study at all, the analyst contends. He reiterates a Buy rating on Amarin with a $10 price target.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.

TODAY'S FREE FLY STORIES

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

07:33
09/25/17
09/25
07:33
09/25/17
07:33
Hot Stocks
Spark Therapeutics appoints Dr. Federico Mingozzi as Chief Scientific Officer »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

AGN

Allergan

$204.65

1.99 (0.98%)

07:32
09/25/17
09/25
07:32
09/25/17
07:32
Hot Stocks
Allergan announces new $2B share repurchase plan, affirms guidance »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ECA

Encana

$11.25

-0.05 (-0.44%)

07:31
09/25/17
09/25
07:31
09/25/17
07:31
Recommendations
Encana analyst commentary  »

Encana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Hot Stocks
Breaking Hot Stocks news story on Allergan »

Allergan announces new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

, ROK

Rockwell Automation

$177.55

0.22 (0.12%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

ROK

Rockwell Automation

$177.55

0.22 (0.12%)

DVA

DaVita

$57.49

-3.77 (-6.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Periodicals
Nintendo adds two-factor authentication for accounts, the Verge says »

Nintendo (NTDOY) users…

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

EGO

Eldorado Gold

$2.26

0.02 (0.89%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Upgrade
Eldorado Gold rating change  »

Eldorado Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

APRN

Blue Apron

$5.19

-0.04 (-0.76%)

07:28
09/25/17
09/25
07:28
09/25/17
07:28
Initiation
Blue Apron initiated  »

Blue Apron initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$188.30

0.39 (0.21%)

07:27
09/25/17
09/25
07:27
09/25/17
07:27
Recommendations
Thermo Fisher analyst commentary  »

Thermo Fisher price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$51.60

4.8 (10.26%)

07:27
09/25/17
09/25
07:27
09/25/17
07:27
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLW

Corning

$30.05

-0.05 (-0.17%)

07:26
09/25/17
09/25
07:26
09/25/17
07:26
Periodicals
Corning looks to expand Gorilla presence in auto glass market, DigiTimes says »

Corning is looking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:26
09/25/17
09/25
07:26
09/25/17
07:26
General news
Futures pointing to slightly lower open »

Stock futures are trading…

ALSSF

Alsea

$3.53

-0.1382 (-3.77%)

07:25
09/25/17
09/25
07:25
09/25/17
07:25
Upgrade
Alsea rating change  »

Alsea upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAA

STAAR Surgical

$10.90

0.05 (0.46%)

07:24
09/25/17
09/25
07:24
09/25/17
07:24
Upgrade
STAAR Surgical rating change  »

STAAR Surgical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$9.32

0.24 (2.64%)

07:24
09/25/17
09/25
07:24
09/25/17
07:24
Technical Analysis
Technical View: Transocean trades higher in pre-market, analyst action »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

ZG

Zillow

$38.93

-0.93 (-2.33%)

07:23
09/25/17
09/25
07:23
09/25/17
07:23
Initiation
Zillow initiated  »

Zillow initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

AMAT

Applied Materials

07:23
09/25/17
09/25
07:23
09/25/17
07:23
Recommendations
Applied Materials analyst commentary  »

Applied Materials analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AEM

Agnico Eagle

$46.74

0.6 (1.30%)

07:23
09/25/17
09/25
07:23
09/25/17
07:23
Recommendations
Agnico Eagle analyst commentary  »

Agnico Eagle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

DK

Delek US

$25.70

0.25 (0.98%)

07:22
09/25/17
09/25
07:22
09/25/17
07:22
Conference/Events
Delek US management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

APOP

Cellect Biotechnology

$8.28

0.19 (2.35%)

07:22
09/25/17
09/25
07:22
09/25/17
07:22
Recommendations
Cellect Biotechnology analyst commentary  »

Cellect Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPX

Louisiana-Pacific

$28.44

0.53 (1.90%)

07:21
09/25/17
09/25
07:21
09/25/17
07:21
Recommendations
Louisiana-Pacific analyst commentary  »

Louisiana-Pacific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSO

CytoSorbents

07:20
09/25/17
09/25
07:20
09/25/17
07:20
Hot Stocks
CytoSorbents highlights publication of study in Journal of Artificial Organs »

CytoSorbents highlighted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRMD

CorMedix

$0.47

0.048 (11.37%)

07:20
09/25/17
09/25
07:20
09/25/17
07:20
Recommendations
CorMedix analyst commentary  »

CorMedix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
09/25/17
09/25
07:20
09/25/17
07:20
General news
FX Update: The euro has come under across-the-board pressure »

FX Update: The euro has…

TWTR

Twitter

$17.61

0.03 (0.17%)

07:19
09/25/17
09/25
07:19
09/25/17
07:19
Periodicals
Twitter tests Twitter Lite Android app in the Philippines, TechCrunch says »

Twitter is testing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.